Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

Abstract: A chainring assembly includes a chainring carrier adapted to be coupled to a crank arm. The chainring carrier is rotatable about a rotation axis, and includes an outer periphery having carrier threads. A chainring structure includes an inner periphery having chainring threads and an outer periphery comprising a plurality of teeth. The inner periphery of the chainring structure is threadably engaged with the outer periphery of the chainring carrier. In one embodiment, a power meter device includes a body having a torque input section and a torque output section, with the torque output section including an outer periphery having threads adapted to be coupled to a chainring structure.

Abstract: Provided herein are immnunodeficient mouse models engrafted with cells comprising a pathogen entry moiety, for example, for assessing pathogenic infection. The pathogen may be a virus, such as a respiratory virus.

Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

Abstract: Provided herein are humanized mouse models and methods for determining whether administration of engineered immune cell therapies likely elicit cytokine release syndrome and/or determining the efficacy of an anti-disease therapy. Further, the models provided herein may be used to test the efficacy of different anti-CRS therapies.

Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

Abstract: This disclosure includes anti-reverse rotation apparatuses, rotors for use therein, and related methods. Some apparatuses include a stator defining an interior volume and one or more arcuate contact surfaces within the interior volume, and a rotor rotatably coupled to the stator and at least partially disposed within the interior volume, the rotor having a hub, two or more shoes, each pivotally coupled to the hub and extending between a first end and a second end that is farther from the hub than is the first end, wherein each of the shoes is rotatable relative to the hub between: (a) a first position in which the second end of the shoe contacts at least one of the arcuate contact surface(s) of the stator; and (b) a second position in which the second end of the shoe does not contact the arcuate contact surface(s) of the stator.

Abstract: This disclosure includes anti-reverse rotation apparatuses, rotors for use therein, and related methods. Some apparatuses include a stator defining an interior volume and one or more arcuate contact surfaces within the interior volume, and a rotor rotatably coupled to the stator and at least partially disposed within the interior volume, the rotor having a hub, two or more shoes, each pivotally coupled to the hub and extending between a first end and a second end that is farther from the hub than is the first end, wherein each of the shoes is rotatable relative to the hub between: (a) a first position in which the second end of the shoe contacts at least one of the arcuate contact surface(s) of the stator; and (b) a second position in which the second end of the shoe does not contact the arcuate contact surface(s) of the stator.

Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

Abstract: Systems and methods are provided for cooling bearings or other objects. Such cooling may be accomplished by expanding a compressed gas in a cooling channel surrounding a bearing and allowing the expanded air to come into direct contact with the bearing. Expanding a compressed gas in local proximity of the bearing takes advantage of the Joule-Thompson expansion of gas, resulting in a substantial drop in gas temperature, thereby maximizing the cooling potential of the gas being directly applied to the bearing. Cooling bearings in this manner extends their operational life and enables them to operate at the desired speeds. A housing may be provided for receiving a compressed gas, expanding the compressed gas to a predetermined pressure, enabling the expanded gas to directly contact the bearing, and exhausting the expanded gas.

Abstract: A fiber-forming bushing comprises a tip plate and a lateral support. The tip plate comprises at least two tip sections and the section spacing between the tip sections. The lateral support extends laterally along the section spacing.

Abstract: A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.